Stock PHXM PHAXIAM THERAPEUTICS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus PHAXIAM Therapeutics S.A. Euronext Paris

Equities

PHXM

FR0011471135

Market Closed - Euronext Paris
Other stock markets
 11:35:26 2024-04-23 am EDT 		5-day change 1st Jan Change
2.92 EUR -0.68% Intraday chart for PHAXIAM Therapeutics S.A. -0.51% -36.52%
Apr. 15 Phaxiam initiates trial in infective endocarditis CF
Apr. 15 PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus CI

Evolution of the average Target Price on PHAXIAM Therapeutics S.A.

Price target over the last 5 years

History of analyst recommendation changes

0e6faf27ea7dd1.befcom7ftDPM75N0I8xBY5s-3DlFHnYn7QUND_1M_Aw.AJCV1h-wwwePmeBHWYYsLe1271gVKTh-hmlDWZscpHxarpDpLeb1RK-spw~30a87ffc364d8c06fb529423f3a6ee8f

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.92 EUR
Average target price
6.85 EUR
Spread / Average Target
+134.59%
High Price Target
8 EUR
Spread / Highest target
+173.97%
Low Price Target
5.7 EUR
Spread / Lowest Target
+95.21%

Consensus detail

Consensus revision (last 18 months)

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. PHXM Stock
  4. PHXM Stock
  5. Consensus PHAXIAM Therapeutics S.A.